Development
ImmunoPrecise Antibodies Ltd.
IPA
$0.6724
-$0.0296-4.22%
NASDAQ
| 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 39.08% | 13.88% | -51.05% | -46.49% | -67.87% |
| Total Depreciation and Amortization | 65.05% | 97.48% | 157.14% | 69.02% | 53.79% |
| Total Amortization of Deferred Charges | -47.58% | -48.87% | -58.18% | 11.97% | -4.50% |
| Total Other Non-Cash Items | 118.07% | 45.11% | 27.07% | -88.35% | -68.95% |
| Change in Net Operating Assets | 66.20% | 111.76% | -617.26% | 164.62% | -256.69% |
| Cash from Operations | 69.48% | 49.56% | -92.01% | -111.27% | -362.69% |
| Capital Expenditure | 21.74% | -78.88% | -31.39% | 25.76% | 3.61% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 97.15% | 80.97% | 84.73% | -732.79% | -732.79% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 124.42% | 143.27% | 125.34% | -279.87% | -226.15% |
| Cash from Investing | 81.55% | 60.36% | 64.26% | -184.51% | -262.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -37.56% | -47.54% | -38.98% | -27.76% | -26.24% |
| Issuance of Common Stock | -97.63% | -84.86% | -81.40% | -86.31% | -86.03% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -142.52% | -127.90% | -120.38% | -90.14% | -89.45% |
| Foreign Exchange rate Adjustments | -68.60% | 466.59% | 48.67% | 195.32% | 160.36% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 62.96% | 44.58% | -76.45% | -221.27% | -205.97% |